XAIR Share Price Performance
US$0.91
-7.91 (-89.67%)
93.5% undervalued intrinsic discount
US$14.00
Fair Value
Price US$0.91
AnalystHighTarget US$14.00
AnalystConsensusTarget US$12.33
AnalystLowTarget US$6.00
Fair ValueUS$14.00
Share Pricen/a
Beyond Air, Inc. Stock Price
- 3 Narratives written by author
- 2 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
XAIR Community Narratives
AN
Fair Value US$14 93.5% undervalued intrinsic discount
Aging Populations And Precision Medicine Will Reshape Respiratory Care
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$12.33 92.6% undervalued intrinsic discount
XAIR: Global Network Expansion Will Drive Long-Term Market Presence
0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AN
Fair Value US$6 84.8% undervalued intrinsic discount
Slow Hospital Onboarding Will Constrain Revenue With Eventual Recovery
0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative
Slow Hospital Onboarding Will Constrain Revenue With Eventual Recovery
Key Takeaways Slow onboarding in hospitals and regulatory hurdles may significantly restrict revenue growth and the ability to capitalize on expanding market access. Heavy reliance on a single core product and growing competition from advanced medtech firms increase both revenue concentration risk and margin pressure.Read more
23
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative
AN
US$6
84.8% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
122.4% p.a.
Profit Margin
12.91%
Future PE
9.02x
Price in 2028
US$4.22
XAIR: Global Network Expansion Will Drive Long-Term Market Presence
Key Takeaways International expansion and partnerships are driving greater market access, positioning the company for sustained revenue growth in advanced respiratory care. Product innovation and operational efficiencies are improving scalability, margin potential, and revenue stability through recurring contracts and long-term customer relationships.Read more
82
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AN
US$12.33
92.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
122.99% p.a.
Profit Margin
12.88%
Future PE
14.06x
Price in 2028
US$8.37
Aging Populations And Precision Medicine Will Reshape Respiratory Care
Key Takeaways Accelerating hospital access and international partnerships could significantly outpace current revenue expectations, fueling rapid global growth opportunities. Recurring revenue from consumables and unique technology positions Beyond Air for strong earnings growth and strategic advantage in a transforming healthcare market.Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$14
93.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
129.04% p.a.
Profit Margin
4.68%
Future PE
40.79x
Price in 2028
US$9.56
Trending Discussion
Recently Updated Narratives
AN
XAIR: Stronger Revenue Outlook And Financing Will Support Future Upside Potential
Fair Value: US$6 84.8% undervalued intrinsic discount
0 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
XAIR: Global Network Expansion Will Drive Long-Term Market Presence
Fair Value: US$12.33 92.6% undervalued intrinsic discount
15 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And Precision Medicine Will Reshape Respiratory Care
Fair Value: US$14 93.5% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Beyond Air, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -4.58
- -6.70%
- -632.49%
- 92.3%
About XAIR
- Founded
- 2011
- Employees
- 61
- CEO
- WebsiteView website
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
